ANI Pharmaceuticals, Inc. (ANIP) Income Statement

The 25.9% YoY growth in 2026Q2, while decelerating from the 53.6% peak in 2025Q3, still represents a robust expansion. The sustained high growth rates suggest that Cortrophin Gel market share gains are the primary driver, as the generic segment faces price erosion. Investors should monitor whether this growth can be maintained as the sales force expansion matures and payer scrutiny intensifies.

The 62.4% gross margin in 2026Q2 is above the 51.0% reported for the full year, indicating that the Rare Disease segment is becoming a larger revenue component. However, the extreme 96.2% margin in 2025Q4 likely reflects a one-time benefit, possibly from a favorable settlement or inventory adjustment. The underlying structural improvement is evident when comparing to the 57-58% margins in 2024, but the sustainability of the 62% level warrants monitoring.

The operating margin expanded from 6.6% in 2025Q2 to 15.2% in 2026Q2, despite a significant increase in SG&A due to the sales force expansion. The SG&A-to-revenue ratio actually declined from 38.7% to 34.5% over the same period, indicating that the sales force is becoming more productive. This leverage is a key driver of the EPS beat and suggests that further margin expansion is possible if revenue growth continues.

The increase in SG&A is a strategic move to capture market share for Cortrophin, but it has kept operating margins below the 19.5% peak seen in 2025Q4. The R&D expense also increased to $14.7M, indicating continued investment in the pipeline. While these costs are necessary for long-term growth, they may limit near-term profitability if revenue growth decelerates.